A new Mucocutaneous Activity Index for Behçet's disease.

MUMCU G., Inanc N., Taze A., Ergun T., DİRESKENELİ R. H.

Clinical and experimental rheumatology, cilt.32, sa.4 Suppl 84, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 4 Suppl 84
  • Basım Tarihi: 2014
  • Dergi Adı: Clinical and experimental rheumatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Behcet's disease, activity, index, mucocutaneous, treatment, symptoms, QUALITY-OF-LIFE, RECURRENT APHTHOUS STOMATITIS, ORAL-HEALTH, CONTROLLED-TRIAL, DOUBLE-BLIND, MANIFESTATIONS, STRATEGIES, SEVERITY, OUTCOMES, ONSET
  • Marmara Üniversitesi Adresli: Evet

Özet

© Clinical and Experimental Rrheumatology 2014.Objective: Patient-reported outcomes are increasingly accepted to be major domains in chronic disorders. The aim of this study was to develop a patient-derived disease activity index in Beh-çet's disease (BD). Methods: One hundred and seventy-seven BD patients (M/F: 69/108) were included in the study. Data were collected by clinical examination and a questionnaire regarding a Mucocutaneous Index (MI) with genital ulcer activity (GI), erythema nodosum activity (EI) and the composite index (CI) for oral ulcers, as subscales of it. Self-reported treatment evaluation was carried out as criterion validity. Patients whose symptoms completely disappeared or decreased significantly, were categorised as "improved group", others were classified as "non-improved group". Results: Among the study group, 79.7% of the patients (n=141) were active, whereas 20.3% were inactive (n=36). Scores of CI, GI, EI and MI score were 0±0 in inactive ones, whereas scores were 5.65±2.36 for CI, 0.81±2.34 for GI, 0.91±2.35 for EI and 6.25±5.1 for MI in actives (p=0.000 for all). MI score was significantly higher in "non-improved group" (65.5%) compared to "improved group" (34.5%) (p < 0.0001). Conclusions: The mucocutaneous activity index may help decision-making process for treatment strategies in BD patients.